{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.0","upperLimit":"64.3","value":"59.7"},{"groupId":"OG001","lowerLimit":"27.7","upperLimit":"36.5","value":"32.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"442"},{"groupId":"OG001","value":"444"}],"units":"Participants"}],"description":"OR was defined as best overall response of CR or PR according to RECIST v1.1 as assessed by investigator recorded from date of randomization until disease progression. CR was defined as complete disappearance of all target and non-target lesions with the exception of nodal disease. All lymph nodes must decrease to normal size (short axis\\<10 mm). All target lesions must be assessed. PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. 95% CI was based on Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"From date of randomization until PD (maximum up to approximately 89 months)","title":"Percentage of Participants With OR as Assessed by Investigator Irrespective of PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}